OM
Opaleye Management Portfolio holdings
AUM
$758M
1-Year Est. Return
77.59%
This Fund
S&P 500
1 Year Est. Return
+77.59%
AUM
$758M
AUM Growth
+$50.6M
(+7.1%)
Holding
64
Top Buys
| 1 | +$42.2M | |
| 2 | +$15M | |
| 3 | +$12.4M | |
| 4 |
Sol-Gel Technologies
SLGL
|
+$9.61M |
| 5 |
UroGen Pharma
URGN
|
+$5.82M |
Top Sells
| 1 | +$37.3M | |
| 2 | +$14M | |
| 3 | +$12.2M | |
| 4 |
Sarepta Therapeutics
SRPT
|
+$11.3M |
| 5 |
Larimar Therapeutics
LRMR
|
+$10.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Atea Pharmaceuticals
AVIR
$452M
| $642K | 0.08% |
+179,815
|
|
||
|
SLN
52
Silence Therapeutics
SLN
$271M
| $480K | 0.06% |
+78,926
|
|
||
|
RAPT
53
DELISTED
RAPT Therapeutics
RAPT
| $213K | 0.03% |
+150,000
|
|
||
|
ADGM
54
Adagio Medical Holdings
ADGM
$36.2M
| $19.2K | ﹤0.01% |
18,444
-92,127
|
|
||
55
Treace Medical Concepts
TMCI
$117M
| – | – |
-702,245
|
|
||
56
Spyre Therapeutics
SYRE
$5.03B
| – | – |
-65,000
|
|
||
|
57
Sarepta Therapeutics
SRPT
$2.22B
| – | – |
-585,000
|
|
||
58
PepGen
PEPG
$117M
| – | – |
-75,000
|
|
||
|
59
Larimar Therapeutics
LRMR
$506M
| – | – |
-3,720,867
|
|
||
60
Immunome
IMNM
$2.45B
| – | – |
-3,185,000
|
|
||
61
iBio
IBIO
$74.6M
| – | – |
-375,000
|
|
||
62
Arvinas
ARVN
$704M
| – | – |
-987,818
|
|
||
63
ADC Therapeutics
ADCT
$475M
| – | – |
-682,529
|
|